Form 4: Apellis CFO Executes Strategic Share Transfer

Apellis Pharmaceuticals CFO Timothy Sullivan transferred 11,096 shares to an irrevocable trust for estate planning purposes.

Summary

• Timothy Sullivan, Chief Financial Officer of Apellis Pharmaceuticals, Inc., transferred 11,096 shares of common stock on April 17, 2026.
• The shares were moved from direct ownership to an indirect holding via The Timothy E Sullivan Irrevocable Trust of 2023.
• Following the transaction, Sullivan maintains direct ownership of 140,945 shares and indirect ownership of 71,492 shares.
• The transaction was executed as a gift (Code G) with a price of $0 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine personal financial transaction by an executive rather than a change in corporate strategy or outlook.

Positives

• The transaction reflects standard estate planning and wealth management activity by a key executive.
• The executive maintains a significant ongoing equity stake in the company, aligning interests with shareholders.

Negatives

• None identified; this is a routine administrative filing regarding beneficial ownership.

Risks

• None identified; this filing pertains to personal asset management rather than corporate operational risk.

Future Outlook

Not applicable; this is a disclosure of a past transaction.

Industry Context

StockSavvy.ai notes that executive share transfers to trusts are common practices for tax and estate planning and generally do not signal a change in confidence regarding the company's future performance.

Comparison to Industry Standards

• The transaction is consistent with standard corporate governance practices for executive officers managing personal portfolios.

Related Party Transactions

• Transfer of 11,096 shares to The Timothy E Sullivan Irrevocable Trust of 2023, where Patrick O. Collins serves as trustee.

Stakeholder Impact

• Minimal impact on shareholders as the total beneficial ownership remains largely unchanged.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, Form 4, Insider Trading, CFO, Beneficial Ownership